In the field of menopause medicine over the last century, women and medical practitioners have been used to discussing about bio-identical hormone replacement therapy. But there is a glitch with this terminology. In reality, you can’t replace your hormones. Instead, hormones can only be copied. We have become accustomed to talking about bio-identical hormone replacement therapy (BHRT) in menopause medicine. The truth, however, is that hormones can’t be replaced – meaning, they’re not really bio-identical. They can only be mimicked and restored.
The latest treatment for women in menopause is multi-phasic rhythmic dosing of bio-mimetic hormone replacement therapy (BHRT) which utilizes natural hormones in a bio-mimetic manner. More than 2 million women in the U.S. make use of customized hormones for menopause symptoms. According to author T.S. Willey, “natural hormones are not bio-mimedic unless the body can recognize them as hormones, and they are not considered restoration unless what has been lost is truly restored.”
A question is presented: would the symptoms of aging disappear if bio-mimedic hormones are dosed to imitate the normal fluctuation of the hormone levels in a young woman’s menstrual cycle? Today, however, a standard for compounded bio-identical hormone replacement protocol is inexistent. A registered pharmacy system was created though, in the absence of the standards of legitimacy and availability, and is ready for testing and study.
Moreover, a new study is underway at the University of Texas and its multi-phasic physiologic dosing will be called Bioidentical Hormones On Trial, or B.H.O.T., a comparison of patterns of administration and dosing of compounded bio-identical hormone therapy (BHT). This study will be the first of its kind to trace and quantify outcomes based on dosing and patterns of administration of BHT. The study will emphasize on evaluating the clinical outcomes and quality of life indicators of patients who received BHT at 10 to 12 primary care provider’s practices.
The findings of the study will be utilized to help establish which dosage and pattern of BHT administration is most effective. Also, the findings will help generate a standard of BHT administration patterns and dosage.
The study is an observational, prospective study of women ages 35 to 60 who are currently using compounded bioidentical hormone therapy (BHT). It’s important to note that regardless of their participation in the study, the respondents will not receive a change in clinical care. The study will have a timeline of three years. Quality of life, symptom relief and impact of BHT on physical health such as breast, endometrial and cardiovascular measures are among the outcomes that will be examined in the study.
What’s more, the results of the study will be presented nationally and internationally, and they will be submitted for publication in different women’s and medical journals. Results will be used to design a prospective, randomized clinical trial with the aim of standardizing BHT dosing and administration patterns.
Among the chief goals of the study are: (1) to examine the quality of life indicators of the patients who are currently receiving BHT at 10-12 practices of primary care providers (2) to check the effectiveness, safety and overall quality of life of respondents who are using 1 among 3 dosing patterns (3)to monitor the women’s lab results (4) to track the adverse effects experienced by the respondents in relation to bioidentical hormone replacement therapy and (5) to assess the compounding pharmacies’ compliance to the standards.
Tags: No Comments
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.